Table 5.
Mortality by HCM status and grade among OSCER patients
| Cancer patients 2009–2013 | |||||
|---|---|---|---|---|---|
| Follow‐up time after cancer diagnosis | |||||
| Frequency | Survival (months) | ||||
| Totala | Deaths | % | Mean | Median | |
| Total cancer patients (OSCER sample) | 117,344 | 13,652 | 11.6% | 22.2 | 14 |
| All hypercalcemia patientsa (grade ≥1) | 3185 | 1094 | 34.3% | 18.9 | 11 |
| HCM grade ≥2 | 731 | 280 | 38.3% | 14.7 | 8 |
| HCM grade ≥3 | 232 | 98 | 42.2% | 15.5 | 7 |
| HCM grade 4 | 95 | 40 | 42.1% | 14.6 | 8 |
| No hypercalcemiab | 114,159 | 12,558 | 11.0% | 22.5 | 14 |
a
Total: All patients linkable to the Experian consumer database (from cancer diagnosis).
b
Log‐rank test of difference in survival between hypercalcemic and normocalcemic cancer patients (χ 2 = 1949, P < 0.0001).